NASDAQ Biotech Stocks Lose 1.6 Trillion Won Amid Clinical Expectations

Incyte Corporation (NASDAQ: INCY) closed at $101.98 on June 15, down 6.04% from the previous day, erasing about $1.16 billion in market capitalization—roughly KRW 1.6 trillion. Trading volume that day was approximately 2.17 million shares.

Incyte recently released updated Phase 1 clinical data for its candidate INCA033989 in patients with mutant CALR–expressing myeloproliferative neoplasms, boosting expectations for its hematologic oncology pipeline. Meanwhile, despite positive results from the pivot Phase 2 PROGRESS study of Zilurgisertib for the rare disease fibrodysplasia ossificans progressiva (FOP), some analysts have maintained an underperform rating after evaluating essential thrombocythemia (ET) and myelofibrosis (MF) trial data, reflecting a cautious stance.

Headquartered in Wilmington, Delaware, Incyte is a biopharmaceutical company expanding its oncology and immunology revenue streams with products such as Jakafi for myelofibrosis and Opzelura for dermatological conditions. With multiple targeted therapies and immuno-oncology agents in clinical development for hematologic malignancies and autoimmune diseases, future pipeline milestones are seen as a key driver of its medium- to long-term corporate value.